The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Stx ARE BURNING 20 ODD MILLION A YEAR CASH IN DEC 13 MILLION work the figures out they need cash soon
One thing I did to ease my mind, spoke to a company representative regarding this narrative of being "delisted from aim". They confirmed that this not something on their agenda.
The remaining relies on how good the results are.
On an upward trajectory now.
Fully funded to cash flow positive
712k buy
What does your last post actually mean
If its in regards to future endorsement of shields only current drug,
you will see that China has no approval as yet and its 6 months late currently
What revenue comes from Canada?
Likewise Korea?
What are the many more catalysts?
Buys
China, Canada, Korea and many more catalysts
Buyers coming in.
Looks like it could be a good one
'Shield has also undertaken several important measures to manage its cash flow, including the reduction of operating expenses, and working capital enhancements, to provide the necessary resources with the aim of turning cash flow positive in the second half of 2025'
It's worded very vaguely, intentionally so.
As for the previous post re 45k scripts Hardman modelled 55k scripts for q4 of last year rising to ~65k by q1 of this year to get to 330k in 2024. 45k scripts won't be anywhere near enough to get them to cash flow break even before the next cash call but I agree it would certainly be reason to be a bit more optimistic, especially if there's any movement on net price per Rx.
Said they have enough cash with cut backs to get to free cash flow in 2025.
I don’t think him telling fibs would be a good idea.
Should see a large rise in sp next week after results and presentation
MMS dropped it on fear
Hi yes. I have done a bit more research.
Need to see 45k scripts for 1st qtr 24 to get this back on track along with a reduction in monthly costs.
It will be tight.
Traxpern,
Do you believe everything in the garden is rosy with the company hiring?
In truth its trying to fill the vacancies after a whole squad of sales people quit there positions....... just dig a little deeper, its never as it first seems.
Https://www.linkedin.com/company/shield-therapeutics?originalSubdomain=uk
Team continues to grow
I don't think feelings will move the stock much, Monday should be interesting.
Enough said, wait until Tuesday and we will see. G/L all
HarChris,
exactly my feelings and it has happened far to often on this stock over the past 18 months..
Sad but true
No leaks here.
Well historically speaking drops like this at STX are because information has leaked and those in the know don't like it.
It is advantageous when the sp has dropped half a penny in a week
It's very rare in situations like this that getting in before results is advantageous, or worth the risk.
Expect a major rise to 2p plus after.
Take your positions now
Indeed. If memory serves correct, even larger inside buys by one or more of the 4D Directors. Look what happened there.
Remind me, how many shares has the CEO bought here?
Regardless, watching with a degree of morbid curiosity to see how this plays out.
Clear expectations for what the ultimate conclusion is going to be of course, but maybe this time it will be different?
I can only imagine that is the basis for anyone taking a punt here right now. Like an unhealthy gambling habit, lol. Your money, your choice of course.
What's the "technical accountants " specialty?
Raising funds I believe.
What was the reason why the last CFO was let go/moved on?
Still on word on the 3rd party.
I've been incredibly bearish since the last results and saw good reason for the slump to 1.5p but there's no doubt that sub 1p is pretty good punt money for a lowball TO in the 2s later this year.
Are you sure?
Were dies your confidence come from?
Research "Connaught" thd new Big shot Boss bought £500k, 2 weeks later it went tits up 20,000 staff gone.
A lot of times directors buys can be very misleading. This is been played out over and over again. However I long for the 6p+ days to come...🙏🙏
London, UK, 27 November 2023: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), confirms that Mr Hans Peter Hasler, Chairman, acquired 2,000,000 Ordinary Shares in the Company on 21 November 2023 at a price of 6.1p per share. Mr Hasler now holds a beneficial interest in 5,500,000 Ordinary Shares.
THIS IS A BUY
The market has almost priced in the worst that can happen but it has not happened yet
At the current price, holding seems more sensible until we see more evidence of a sudden business downturn from the corrected position they have already declared.
There are many AIM companies in similar positions and if the sales are still growing at the stated rate and the new accountant has a grip on costs there will at some point be an SP recovery. (results next Tuesday)